

Financial news for FATE dated on 2020-06-09: Fate Therapeutics shares are trading. The company late Monday priced its 6.18 million share common stock offering at \$28.31 per share.

Financial news for FATE dated on 2020-06-08: Fate Therapeutics Announces Proposed Public Offering of Common Stock; No Terms Disclosed

Financial news for FATE dated on 2020-05-20: Fate Therapeutics Reports FDA Clearance For Investigational New Drug Application For FT538, CRISPR-Edited, iPSC-Derived Cell Therapy

Financial news for FATE dated on 2020-05-13: HC Wainwright & Co. Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of \$42

Financial news for FATE dated on 2020-05-12: BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to \$29

Financial news for FATE dated on 2020-05-11: Fate Therapeutics Q1 EPS \$(0.440) Misses \$(0.390) Estimate, Sales \$2.515M Beat \$1.800M Estimate

Financial news for FATE dated on 2020-04-06: Oppenheimer Maintains Outperform on Fate Therapeutics, Lowers Price Target to \$34

Financial news for FATE dated on 2020-04-03: Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to \$41

Financial news for FATE dated on 2020-04-02: Fate Therapeutics Announces Worldwide Collaboration With Janssen For Novel IPSC-derived Cell-Based Cancer Immunotherapies; Co. To Receive \$50M Upfront And \$50M Equity Investment And Eligible To Receive Up To \$1.8B

Financial news for FATE dated on 2020-04-02: Fate Therapeutics Announces First Patient Treated In First-in-Human Clinical Trial Of FT596 And Provides Corporate Update

Financial news for FATE dated on 2020-03-04: Fate Therapeutics shares are trading higher after Barclays and Citigroup issued bullish ratings on the stock.

Financial news for FATE dated on 2020-03-04: Citigroup Maintains Buy on Fate Therapeutics, Raises Price Target to \$41

Financial news for FATE dated on 2020-03-04: Barclays Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces \$40 Price Target

Financial news for FATE dated on 2020-03-03: Oppenheimer Maintains Outperform on Fate Therapeutics, Raises Price Target to \$36

Financial news for FATE dated on 2020-03-02: Fate Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for FATE dated on 2020-03-02: Fate Therapeutics Q4 EPS \$(0.37) Beats \$(0.39) Estimate, Sales \$2.802M Beat \$1.8M Estimate

Financial news for FATE dated on 2020-02-26: Mizuho Maintains Buy on Fate Therapeutics, Raises Price Target to \$40

Financial news for FATE dated on 2020-02-14: Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to \$33

Financial news for FATE dated on 2020-01-13: Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

Financial news for FATE dated on 2019-12-30: Mizuho Reiterates Buy on Fate Therapeutics, Raises Price Target to \$33

Financial news for FATE dated on 2019-12-09: BMO Capital Maintains Outperform on Fate Therapeutics, Lowers Price Target to \$22

Financial news for FATE dated on 2019-12-09: Fate Therapeutics shares are trading higher after the company announced positive preliminary data from its FT596 study and Wells Fargo upgraded its rating of the stock to Outperform.

Financial news for FATE dated on 2019-12-09: Wells Fargo Upgrades Fate Therapeutics to Outperform, Announces \$24 Price Target

Financial news for FATE dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$25 Price Target

Financial news for FATE dated on 2019-11-06: BMO Capital Maintains Outperform on Fate

Therapeutics, Lowers Price Target to \$26

Financial news for FATE dated on 2019-11-06: Wells Fargo Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to \$16

Financial news for FATE dated on 2019-11-05: Fate Therapeutics Q3 EPS \$(0.4) Misses \$(0.38) Estimate, Sales \$2.4M Beat \$1.79M Estimate

Financial news for FATE dated on 2019-10-01: UPDATE: Stifel Initiates Fate Therapeutics With Buy, \$27 Target As Firm Notes 'We think the next clinical catalyst for FT500 and FT516 will be positive events for the stock'

Financial news for FATE dated on 2019-10-01: Stifel Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$27 Price Target

Financial news for FATE dated on 2019-09-16: Piper Jaffray Maintains Overweight on Fate Therapeutics, Lowers Price Target to \$28

Financial news for FATE dated on 2019-09-11: Fate Therapeutics shares are trading lower after the company reported a common stock offering with no size disclosed.

Financial news for FATE dated on 2019-09-11: Fate Therapeutics Reports Common Stock Offering, Size Not Disclosed

Financial news for FATE dated on 2019-08-14: Fate Therapeutics Announces Issuance Of Foundational US Patent Covering iPSC-Derived CAR T Cells

Financial news for FATE dated on 2019-08-09: BTIG Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$27 Price Target

Financial news for FATE dated on 2019-08-06: Fate Therapeutics Q2 EPS \$(0.36) Misses \$(0.33) Estimate, Sales \$2.817M Up From \$1.027M YoY

Financial news for FATE dated on 2019-07-22: UPDATE: Cantor Fitzgerald Initiates Fate Therapeutics With Overweight, \$32 Tgt As Firm Thinks Co. 'is pioneering a highly scalable next-generation cell-therapy manufacturing process using induced pluripotent stem cells (iPSCs) that could be first class'

Financial news for FATE dated on 2019-07-22: Cantor Fitzgerald Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces \$32 Price Target

Financial news for FATE dated on 2019-07-12: Oppenheimer Initiates Coverage On Fate Therapeutics with Outperform Rating, Announces \$27 Price Target

Financial news for FATE dated on 2019-06-13: Mizuho Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$27 Price Target

Financial news for FATE dated on 2019-06-07: Roth Capital Initiates Coverage On Fate Therapeutics with Neutral Rating, Announces \$20 Price Target

Financial news for FATE dated on 2019-05-31: Guggenheim Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$25 Price Target

Financial news for FATE dated on 2019-05-24: Citi Assumes Fate Therapeutics, Inc. - Common Stock at Buy, Raises Price Target \$26

Financial news for FATE dated on 2019-05-07: Fate Therapeutics Announces FT500 Clinical Trial Now Open for Enrollment in Checkpoint Inhibitor Combination Arm for Treatment of Advanced Solid Tumors

Financial news for FATE dated on 2019-05-07: Fate Therapeutics Announces No Dose-Limiting Toxicities or Serious Adverse Events Reported in Initial Cohort of FT500 iPSC-derived NK Cell Cancer Immunotherapy Patients

Financial news for FATE dated on 2019-05-07: Fate Therapeutics Announces First-Ever Patient Treated In U.S. With An IpSC-Derived Cell Therapy Successfully Advances Through Six-Dose Treatment Course

Financial news for FATE dated on 2019-05-07: Fate Therapeutics Q1 EPS \$(0.3) Misses \$(0.24) Estimate, Sales \$2.632M Beat \$2.37M Estimate

Financial news for FATE dated on 2019-04-24: Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting

Financial news for FATE dated on 2019-04-02: Fate Therapeutics Announces First Patient Treated With iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment

Financial news for FATE dated on 2019-04-01: Fate Therapeutics Highlights

Presentation Of Late-Breaking Preclinical Data Highlighting Unique Advantages Of Clonal Master Engineered iPSC Lines For Off-The-Shelf CAR T-cell Therapy At 2019 AACR Annual Meeting

Financial news for FATE dated on 2019-03-28: SVB Leerink Initiates Coverage On Fate Therapeutics with Outperform Rating, Announces \$20 Price Target

Financial news for FATE dated on 2019-03-05: Fate Therapeutics Q4 EPS \$(0.25) Misses \$(0.24) Estimate, Sales \$1.661M Miss \$2.89M Estimate

Financial news for FATE dated on 2019-02-06: Fate Therapeutics Announces FDA Clearance Of IND Application For Cell Therapy Derived From Engineered Pluripotent Stem Cell

Financial news for FATE dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for FATE dated on 2018-12-03: Fate Therapeutics Secures Exclusive Option To Novel Humanized Anti-BCMA CAR Constructs For Development Of iPSC-derived Cell Products

Financial news for FATE dated on 2018-11-30: Fate Therapeutics shares are trading higher after the company announced receipt of FDA clearance of an Investigational New Drug application for its FT500 cell cancer therapy.

Financial news for FATE dated on 2018-11-30: Fate Therapeutics Announces FDA Clearance Of Landmark IND For FT500 iPSC-Derived, Off-the-Shelf NK Cell Cancer Immunotherapy

Financial news for FATE dated on 2018-11-05: Jefferies Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$17 Price Target

Financial news for FATE dated on 2018-11-01: Fate Therapeutics Q3 EPS \$(0.31) Misses \$(0.25) Estimate, Sales \$1.026M Miss \$2.87M Estimate

Financial news for FATE dated on 2018-11-01: Fate Therapeutics Announces Seven Presentations At The 2018 ASH Annual Meeting Dec 1-4

Financial news for FATE dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for FATE dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for FATE dated on 2018-09-25: Stocks Which Set New 52-Week High Yesterday, September 24th

Financial news for FATE dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for FATE dated on 2018-09-21: Fate Therapeutics Prices 9.2M Share Public Offering of Common Stock @\$13.50/Share

Financial news for FATE dated on 2018-09-20: Fate Therapeutics Reports Offering Of Common Shares, No Size Disclosed

Financial news for FATE dated on 2018-09-18: Fate Therapeutics Late Monday Announced Strategic Collaboration With ONO Pharmaceutical To Develop Off-The-Shelf, iPSC-Derived CAR-T Cell Cancer Immunotherapies

Financial news for FATE dated on 2018-09-13: Fate Therapeutics Enters Into Exclusive License Agreement With Gladstone Institutes For CRISPR-Based Cellular Reprogramming, New Approach Uses CRISPR-Mediated Genome Activation For iPSC Generation

Financial news for FATE dated on 2018-08-06: Fate Therapeutics Q2 EPS \$(0.37) Misses \$(0.31) Estimate, Sales \$1.03M Miss \$1.18M Estimate

Financial news for FATE dated on 2018-08-01: Citigroup Initiates Coverage On Fate Therapeutics with Buy Rating, Announces \$20 Price Target

Financial news for FATE dated on 2018-05-16: Fate Therapeutics Reports Expanded Scope Of Licensing Deal With Memorial Sloan Kettering Cancer Center To Include Gene-Edited T-Cell Immunotherapies, No Terms Disclosed

Financial news for FATE dated on 2018-05-10: Fate Therapeutics Q1 EPS \$(0.27) Misses \$(0.22) Estimate, Sales \$1.026M Miss \$1.68M Estimate

Financial news for FATE dated on 2018-05-04: Fate Therapeutics S-3 Shows Registration For \$150M Mixed Securities Shelf

Financial news for FATE dated on 2018-03-29: Fate Therapeutics Reports Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer: 'Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100'

Financial news for FATE dated on 2018-03-06: Fate Therapeutics Shares Down 7.8% Following Q4 EPS Miss Reported Monday

Financial news for FATE dated on 2018-03-06: BMO Capital Maintains Outperform on Fate Therapeutics, Raises Price Target to \$20.00

Financial news for FATE dated on 2018-03-06: H.C. Wainwright Downgrades Fate Therapeutics to Neutral, Raises Target to \$12.00

Financial news for FATE dated on 2018-03-06: Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to \$19.00

Financial news for FATE dated on 2018-03-05: Fate Therapeutics Reports Q4 EPS \$(0.29) vs \$(0.24) Est., Sales \$1M vs \$940K Est.

Financial news for FATE dated on 2018-01-24: Fate Therapeutics Shares Down 7.9% On Potential Profit-Taking After Making New 52-Week High Tuesday

Financial news for FATE dated on 2018-01-23: Fate Therapeutics Shares Make New 52-Week High Of \$9.78, Now Up 9.65% On ~4x Avg. Volume At \$9.09

Financial news for FATE dated on 2017-12-22: Fate Therapeutics Shares Continuing Higher Fri., Up 12%; Stock Up Nearly 30% Over Last 3 Sessions; Amended 13G Filing From Redmile Tues. Afternoon Showed Raised Stake From ~1.4M Shares At End Of Last Qtr. To ~6.6M Shares, Or 12.6% Stake

Financial news for FATE dated on 2017-12-18: PiperJaffray Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces \$10.00 Price Target

Financial news for FATE dated on 2017-12-13: Fate Therapeutics Prices 9.525M Share Offering at \$4.20/Shre

Financial news for FATE dated on 2017-12-12: Fate Therapeutics Announces Common Stock Offering, No Size Disclosed

Financial news for FATE dated on 2017-12-12: Watch Shares of Fate Therapeutics After the Company Earlier Gave an Update on its Phase 1 PROTECT Trial

Financial news for FATE dated on 2017-12-08: Fate Therapeutics Reports 1st Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer

Financial news for FATE dated on 2017-11-10: Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 Shows No Dose Limiting Toxicities Reported, Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14

Financial news for FATE dated on 2017-11-01: Fate Therapeutics Q3 EPS \$(0.26) vs \$(0.24) Est., Sales \$1.03M vs \$0.93M Est.

Financial news for FATE dated on 2017-10-12: H.C. Wainwright Assumes Fate Therapeutics at Buy, Announces price target \$7.00

Financial news for FATE dated on 2017-08-16: Fate Therapeutics Reports Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy

Financial news for FATE dated on 2017-08-14: Fate Therapeutics Reports Q2 EPS \$(0.23) vs \$(0.24) Est., Sales \$1.026M vs \$940K Est.

Financial news for FATE dated on 2017-08-08: Fate Therapeutics Reports FDA Clearance Of Third IND For FATE-NK100

Financial news for FATE dated on 2017-05-15: Fate Therapeutics Reports Q1 EPS \$(0.24) vs \$(0.20) Est., Sales \$1.027M vs \$950K Est.

Financial news for FATE dated on 2017-05-10: Fate Therapeutics Reports FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors

Financial news for FATE dated on 2017-03-16: Fate Therapeutics Reports Q4 EPS \$(0.21) vs \$(0.29) Est., Sales \$1.027M vs \$960K Est.

Financial news for FATE dated on 2017-03-13: Fate Therapeutics Reports FDA Clearance of Investigational NDA for FATE-NK100 Immunotherapy

Financial news for FATE dated on 2017-02-28: Wedbush Reiterates Outperform On Fate

Therapeutics, Maintains \$7 Price Target

Financial news for FATE dated on 2017-02-15: Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma

Financial news for FATE dated on 2017-01-25: Filing from Fate Therapeutics Shows Registration for ~20.86M Share Common Stock Offering via Selling Holders

Financial news for FATE dated on 2016-09-22: Roth Capital Initiates Coverage on Fate Therapeutics at Buy

Financial news for FATE dated on 2016-07-28: H.C. Wainwright Assumes Fate Therapeutics at Buy

Financial news for FATE dated on 2016-04-12: BMO Capital Initiates Coverage on Fate Therapeutics at Outperform, Announces \$4.00 PT

Financial news for FATE dated on 2015-12-04: Wells Fargo Initiates Coverage on Fate Therapeutics at Outperform

Financial news for FATE dated on 2015-10-06: Raymond James Initiates Coverage on Fate Therapeutics at Outperform, Announces \$8.00 PT

Financial news for FATE dated on 2015-06-01: Leerink Swann Initiates Coverage on Fate Therapeutics at Outperform, Announces \$10.00 PT

Financial news for FATE dated on 2015-05-21: Fate Therapeutics Prices 6M Share Offering @\$5.00/Share

Financial news for FATE dated on 2014-12-18: Fate Therapeutics Announces Positive Initial Data from Ongoing Phase 2 PUMA Study

Financial news for FATE dated on 2014-12-06: Fate Therapeutics Presents Positive Preclinical Data on Ex Vivo Programmed Hematopoietic Cells at ASH Annual Meeting

Financial news for FATE dated on 2014-08-12: Fate Therapeutics Reports Q2 EPS of \$(0.30) vs \$(0.36) Est

Financial news for FATE dated on 2014-07-31: Fate Therapeutics Announces Up to \$20M in Debt Financing

Financial news for FATE dated on 2014-05-13: Fate Therapeutics Reports Q1 EPS of \$(0.34) vs \$(0.33) Est

Financial news for FATE dated on 2014-03-17: Fate Therapeutics Reports Q4 EPS of \$(0.29) vs \$(0.27) Est

Financial news for FATE dated on 2014-03-12: Fate Therapeutics Initiates Phase 2 Clinical Trial of PROHEMA for Treatment of Hematologic Malignancies

Financial news for FATE dated on 2014-02-26: Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment from Phase 1b Study of PROHEMA

Financial news for FATE dated on 2013-11-13: Fate Therapeutics Reports Q3 EPS of \$(4.81) Which May Not Compare \$(0.32) Est; Revenue of \$209.0K

Financial news for FATE dated on 2013-10-28: UPDATE: Wedbush Initiates Coverage on Fate Therapeutics on Potential of Modified HSCs

Financial news for FATE dated on 2013-10-28: Cowen Initiated Coverage on Fate Therapeutics with an Outperform Rating

Financial news for FATE dated on 2013-10-28: BMO Initiates Fate Therapeutics with Outperform Rating, \$11 Price Target

Financial news for FATE dated on 2013-10-01: Fate Therapeutics IPO Opens at \$6.56 After Pricing at \$6

Financial news for FATE dated on 2013-10-01: Quoting in IPO for Fate Therapeutics Now Open, Issue Expected to Begin Trade at 11AM EDT

Financial news for FATE dated on 2013-10-01: Fate Therapeutics Prices IPO of 6.7M Shares at \$6/Share